Sotera Health (NASDAQ:SHC) Issues FY 2025 Earnings Guidance

Sotera Health (NASDAQ:SHC) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 0.700-0.760 for the period, compared to the consensus EPS estimate of 0.780. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SHC. The Goldman Sachs Group began coverage on shares of Sotera Health in a report on Friday, December 6th. They issued a “neutral” rating and a $14.00 price target on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $17.00 price target on shares of Sotera Health in a report on Thursday, November 21st. Citigroup raised their price target on shares of Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, Barclays lowered their price target on shares of Sotera Health from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Sotera Health has a consensus rating of “Moderate Buy” and a consensus price target of $16.08.

Sotera Health Stock Down 0.7 %

SHC stock opened at $13.64 on Thursday. The firm has a 50 day moving average of $13.48 and a 200 day moving average of $14.54. The stock has a market capitalization of $3.86 billion, a PE ratio of 54.56 and a beta of 1.91. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. Sotera Health has a 52 week low of $10.71 and a 52 week high of $17.44.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.21 by ($0.02). Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. Sell-side analysts forecast that Sotera Health will post 0.61 earnings per share for the current year.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.